Bleeding Risk Prediction in Patients With Dual Antiplatelet Therapy Undergoing Coronary Artery Bypass Grafting Surgery Using a Rapid Point-of-Care Platelet Function Test

Circ Cardiovasc Interv. 2018 Dec;11(12):e007264. doi: 10.1161/CIRCINTERVENTIONS.118.007264.

Affiliations

¹ Department of Cardiology, Hospital Clínico Universitario Virgen de la Arrixaca, Instituto Murciano de Investigación Biosanitaria (IMIB-Arrixaca), CIBERCV, Murcia, Spain (A.T.-M., D.H.-R., A.V., C.L.-G., M.V., J.M.R.-C., F.M.).
² Department of Cardiovascular Surgery, Hospital Clínico Universitario Virgen de la Arrixaca, IMIB-Arrixaca, Murcia, Spain (P.A., R.T., J.M.A., A.V., S.C.).
³ Intensive Care Unit, Hospital Clínico Universitario Virgen de la Arrixaca, Murcia, Spain (C.L.A., R.J.).

PMID: 30525983
DOI: 10.1161/CIRCINTERVENTIONS.118.007264

No abstract available

Keywords: acute coronary syndrome; aspirin; coronary artery bypass; platelet aggregation inhibitors; platelet function tests.

Publication types

Letter
Observational Study
Research Support, Non-U.S. Gov't

MeSH terms

Acute Coronary Syndrome / blood
Acute Coronary Syndrome / diagnosis
Acute Coronary Syndrome / surgery*
Aged
Aspirin / administration & dosage
Aspirin / adverse effects*
Clinical Decision-Making
Coronary Artery Bypass / adverse effects*
Drug Therapy, Combination
Female
Humans
Male
Middle Aged
Patient Selection
Platelet Aggregation Inhibitors / administration & dosage
Platelet Aggregation Inhibitors / adverse effects*
Platelet Function Tests*
Point-of-Care Testing*
Postoperative Hemorrhage / chemically induced*
Predictive Value of Tests
Prospective Studies
Purinergic P2Y Receptor Antagonists / administration & dosage
Purinergic P2Y Receptor Antagonists / adverse effects*
Reproducibility of Results
Risk Assessment
Risk Factors
Treatment Outcome

Substances

Platelet Aggregation Inhibitors
Purinergic P2Y Receptor Antagonists
Aspirin